

# Impact of Lung Function Decline on Time to Hospitalisation Events in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): a Joint Model Analysis

**Michael Kreuter** (✉ [kreuter@uni-heidelberg.de](mailto:kreuter@uni-heidelberg.de))

UniversitätsKlinikum Heidelberg <https://orcid.org/0000-0003-4402-2159>

**Francesco Del Galdo**

Scleroderma Programme NIHR BRC and Institute of Rheumatic and Musculoskeletal Medicine,  
University of Leeds

**Corinna Miede**

mainanalytics GmbH

**Dinesh Khanna**

Division of Rheumatology/Department of Internal Medicine, Scleroderma Program, University of  
Michigan

**Wim A. Wuyts**

Interstitial Lung Diseases Unit, University Hospitals Leuven

**Laura K. Hummers**

Johns Hopkins Rheumatology: Johns Hopkins Medicine Division of Rheumatology

**Margarida Alves**

Boehringer Ingelheim International GmbH

**Nils Schoof**

Boehringer Ingelheim International GmbH

**Christian Stock**

Boehringer Ingelheim Pharma GmbH and Co KG

**Yannick Allanore**

Hospital Cochin Rheumatology Institute: Hopital Cochin Institut de Rhumatologie

---

## Research article

**Keywords:** joint model, SENSICIS, systemic sclerosis-associated interstitial lung disease, surrogate endpoint, hospitalisation, forced vital capacity

**Posted Date:** June 1st, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-562095/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Arthritis Research & Therapy on January 10th, 2022. See the published version at <https://doi.org/10.1186/s13075-021-02710-9>.

# Abstract

**Background:** Interstitial lung disease (ILD) is a common organ manifestation in systemic sclerosis (SSc) and is the leading cause of death in patients with SSc. A decline in forced vital capacity (FVC) is an indicator of ILD progression and is associated with mortality in patients with SSc-associated ILD (SSc-ILD). However, the relationship between FVC decline and hospitalisation events in patients with SSc-ILD is largely unknown. The objective of this post-hoc analysis was to investigate the relationship between FVC decline and clinically important hospitalisation endpoints.

**Methods:** We used data from SENSICIS<sup>®</sup>, a Phase III trial investigating the efficacy and safety of nintedanib in patients with SSc-ILD. Joint models for longitudinal and time-to-event data were used to assess the association between rate of decline in FVC% predicted and hospitalisation-related endpoints (including time to first all-cause hospitalisation or death; time to first SSc-related hospitalisation or death; and time to first admission to an emergency room [ER] or admission to hospital followed by admission to intensive care unit [ICU] or death) during the treatment period, over 52 weeks in patients with SSc-ILD.

**Results:** There was a statistically significant association between FVC decline and the risk of all-cause (n=78) and SSc-related (n=42) hospitalisations or death (both  $P < 0.0001$ ). A decrease of 3% in FVC corresponded to a 1.43-fold increase in risk of all-cause hospitalisation or death (95% confidence interval [CI] 1.24, 1.65) and a 1.48-fold increase in risk of SSc-related hospitalisation or death (95% CI 1.23, 1.77). No statistically significant association was observed between FVC decline and admission to ER or to hospital followed by admission to ICU or death (n=75;  $P = 0.15$ ). The estimated slope difference for nintedanib versus placebo in the longitudinal sub-model was consistent with the primary analysis in SENSICIS<sup>®</sup>.

**Conclusions:** The association of lung function decline with an increased risk of hospitalisation suggests that slowing FVC decline in patients with SSc-ILD may prevent hospitalisations. Our findings also provide evidence that FVC decline may serve as a surrogate endpoint for clinically relevant hospitalisation-associated endpoints.

**Trial registration:** Clinicaltrials.gov, NCT02597933. Registered 8 October 2015, <https://clinicaltrials.gov/ct2/show/study/NCT02597933>.

## Background

Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by extensive fibrosis of the skin, internal organs and vasculopathy [1]. Interstitial lung disease (ILD) is a common manifestation of SSc, in which parenchymal involvement can lead to pulmonary fibrosis and declining pulmonary function [2, 3]. SSc-associated ILD (SSc-ILD) is associated with reduced survival and is the leading cause of death in patients with SSc [4].

Reductions in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide ( $DL_{CO}$ ) are indicative of ILD progression and associated with mortality in patients with SSc-ILD [5, 6]. Other aspects of ILD progression – worsening symptoms (e.g. dyspnoea); deterioration of health-related quality of life (HRQoL); and increase in the extent of fibrosis on high-resolution computed tomography (HRCT) – can be either attributed to other aspects of the systemic disease or are not systematically and regularly assessed [7]. FVC is currently supported as an endpoint for randomised controlled trials and is the primary outcome measure in many of them [8, 9].

An FVC absolute decline of at least 10% is an established measure of progression in more progressive ILDs like idiopathic pulmonary fibrosis (IPF) [10], but in SSc-ILD lower levels of progression may better reflect the disease course. For instance, an FVC absolute decline of 5–9% with a  $DL_{CO}$  absolute decline of  $\geq 15\%$  has been considered optimal for trial purposes [6], and an FVC decline or improvement of approximately 3% was considered a minimal clinically important difference based on data from Scleroderma Lung Study I and II [9].

Although FVC is important, patient-reported outcome (PRO) measures have recently received growing recognition as they can provide valuable insights about the impact of a disease on patients and drive improvements in care [11]. Studies have shown that cough, dyspnoea, changes in physical function and fatigue are the lung-related symptoms of most concern to patients with connective tissue disease (CTD)-associated ILD, including SSc [12, 13]. Thus, PRO measures are usually assessed in randomised clinical trials in SSc-ILD as secondary endpoints [14]. In the Phase III SENSICIS® trial, very small changes in PRO measures were observed over 52 weeks, with no differences between nintedanib and placebo. Post-hoc analysis showed that patients with more impaired lung function (FVC < 70% predicted at baseline) had worse HRQoL (as indicated by higher St. George's Respiratory Questionnaire values), and that a moderate or large decline in lung function was associated with a more pronounced decline in HRQoL [15]. Nevertheless, defining relationships between pulmonary function test and PRO measures remains a significant challenge in ILD.

Hospitalisation is recognised as a serious event by both patients and physicians, and has clear health-economic implications. The frequency of hospitalisations and emergency room (ER) visits was considered important to a CTD-ILD patient focus group [12]. Furthermore, longitudinal data from the German INSIGHTS-IPF registry suggested an association between hospitalisation and poorer HRQoL in patients with IPF [16]. Existing data have demonstrated that patients with SSc-ILD have a higher economic burden compared with patients with other organ involvement associated with SSc, which has been largely attributed to inpatient hospitalisations [3]. In addition, several US-based studies have agreed that SSc-ILD is associated with greater healthcare costs compared with SSc alone [17–19]. For patients with incident SSc-ILD, healthcare costs in the USA are nearly twice as high over 5 years compared with patients with incident SSc [17].

Nintedanib is a multi-target tyrosine kinase inhibitor with anti-inflammatory and antifibrotic properties approved for the treatment of patients with SSc-ILD in the USA, Japan, Europe and several countries

worldwide, based on the results of the SENSISCIS® clinical trial. This large, randomised, placebo-controlled, parallel trial demonstrated a statistically significant 44% reduction in ILD progression in patients with SSc-ILD receiving nintedanib, compared with those who received placebo (mean adjusted annual rate of FVC decline over 52 weeks in patients in the nintedanib and placebo arms of - 52.4 mL/year vs. - 93.3 mL/year, respectively; P = 0.04) [20].

In cases where clinically relevant endpoints are difficult to measure or particularly rare in clinical trials, surrogate endpoints such as biomarkers may be a suitable substitute if the two endpoints are known to be correlated. This is also an option for hospitalisation and mortality outcomes in slow, progressive diseases such as SSc-ILD, where large sample sizes and long follow-up times would be required due to low event incidence [21]. A biomarker of SSc-ILD progression such as FVC decline may be able to serve as a surrogate for hospitalisation endpoints if a relationship could be established.

Joint modelling allows for the combined analysis of longitudinal and time-to-event endpoints in a single model and to assess the validity of the potential surrogate endpoint [22, 23]. If an association is identified and a treatment effect on the surrogate endpoint is also established, this provides evidence of an indirect treatment effect on the clinically important endpoint [24].

The objective of this post-hoc analysis was to investigate the association between longitudinal FVC decline and time to hospitalisation endpoints in SSc-ILD using data from the SENSISCIS® trial.

## Methods

### Data source

The design and eligibility criteria for SENSISCIS® have been reported previously [20]. Briefly, adult patients with SSc [25] were enrolled if they had disease onset (first non-Raynaud symptom of SSc) within the previous 7 years, evidence of lung fibrosis in  $\geq 10\%$  of the lung using HRCT, an FVC  $\geq 40\%$  of the predicted value, and haemoglobin-corrected  $DL_{CO}$  30–89% of the predicted value. Evidence of previous ILD progression was not required for entry into SENSISCIS®. Eligible patients were randomised in a double-blind fashion to receive either nintedanib (n=288) or placebo (n=288) for up to 100 weeks or until the last randomised patient reached 52 weeks of treatment, with the primary efficacy evaluation (annual rate of decline in FVC [mL/ year]) conducted at 52 weeks. Concomitant treatment with prednisone  $\leq 10$  mg/day (or equivalent) and/or stable therapy with mycophenolate or methotrexate for  $\geq 6$  months prior to randomisation was allowed. Additional therapy was allowed during the treatment period if clinically significant deterioration occurred. Patients were stratified according to the presence of anti-topoisomerase I antibody (ATA), which is associated with declining FVC in patients with early SSc [20, 26].

### Included time-to-event and longitudinal endpoints

The two outcome variables considered in this study and analysed together in a joint model were defined as follows. Various time to hospitalisation endpoints in the context of the SENSISCIS<sup>®</sup> trial period (over 52 weeks and the whole trial) were considered for inclusion in a joint model. These were: 1) time to first all-cause hospitalisation or death; 2) time to first SSc-related hospitalisation or death; 3) time to first admission to the ER or admission to hospital followed by admission to an intensive care unit (ICU) or death; 4) time to first admission to hospital followed by admission to ICU or death; and 5) time to first admission to hospital followed by use of mechanical ventilation or death. Hospitalisation-associated events, including those associated with SSc, were reported and verified by clinicians. Only hospitalisations that occurred during the treatment period or 28 days thereafter were considered.

The longitudinal response variable was the rate of decline in FVC% predicted over 52 weeks and the whole trial. Only values obtained from on-treatment assessments were considered for inclusion. In a secondary analysis, we further considered the FVC% predicted at a given time (i.e. irrespective of the slope) as longitudinal response.

## **Statistical analysis**

The total sample and subsamples of patients with and without hospitalisation events were characterised using standard descriptive statistics. Joint modelling for longitudinal and time-to-event data was used to assess the association between rate of decline in FVC% predicted and hospitalisation-related endpoints [21, 22]. The approach was implemented using the SAS<sup>®</sup> macro %JM [27], and validated using the R package JM, version 1.4-8 [28].

## **Longitudinal sub-model**

We used a normal mixed effects model of FVC% predicted with ATA status and FVC% predicted at baseline as predictor variables. Separate mean slopes for patients on nintedanib treatment and controls were assumed, and trajectories were modelled by a linear trend with an unstructured variance-covariance matrix assumed, given the known effect of nintedanib on FVC. All FVC values in the SENSISCIS<sup>®</sup> trial were used: visits at 2, 4, 6, 12, 24, 36 and 52 weeks (visits 3 to 9) for the 52-week time period; and visits at 68, 84 and 100 weeks (visit 10 to 12) for whole trial period. Only on-treatment FVC measurements before a hospitalisation event were considered.

## **Time to event sub-model**

For the time to event sub-model, a piecewise exponential model with five internal knots was used to model the baseline hazard. This is a standard approach used in joint modelling of longitudinal and time-to-event data where the baseline hazard is usually modelled explicitly. It assumes that hazards are constant over the particular time intervals and avoids misspecification of time-to-event distribution. FVC% predicted (i.e. the longitudinal response) was used as the endogenous time-dependent covariate, and the time to event sub-model was additionally stratified by ATA status.

## Association structure

The shared parameter in each of the joint models was FVC% predicted, which was considered as either the “estimated slope” (assuming the rate of FVC% predicted affected the risk of an event occurring; primary analysis) or the “estimated current value” (assuming the risk of a hospitalisation event at a given time depended on the estimated value of FVC% predicted at that time; secondary analysis). In compliance with recommended reporting, all model coefficients and their precisions are available in Supplementary Methods S1–6 [29].

For each hospitalisation endpoint observed during the SENSICIS® trial with sufficient numbers of events across two time periods (52 weeks and whole trial), joint models were fitted. We present the risk of first hospitalisation events in terms of 1-, 3- and 5-unit FVC decline, as well as graphically from >0 to 10-unit FVC decline. A “unit” here represents 1 percentage point. Results with a P-value  $\leq 0.05$  were considered statistically significant.

## Results

### Participant characteristics

A total of 576 participants were enrolled in the SENSICIS® trial and received at least one dose of nintedanib or placebo. FVC and hospitalisation data was available for 574 patients and were therefore included in this analysis. The baseline characteristics of all patients included in the joint models and those with a hospitalisation event or death during the trial period are described in Table 1. Most patients were female (75.1%). Approximately 50% of patients had diffuse cutaneous SSc and 60.8% of the total population were ATA positive. The mean FVC% predicted ( $\pm$  standard deviation [SD]) at baseline was  $72.5 \pm 16.7$  for the total population,  $72.0 \pm 16.4$  and  $70.5 \pm 18.7$  for patients with all-cause and SSc-related hospitalisation events or death, and  $70.9 \pm 16.7$  for patients with ER or hospital admission followed by admission to ICU or death. The annual rate of decline in FVC% predicted for patients enrolled in SENSICIS® was  $-1.4 \pm 0.4\%$  and  $-2.6 \pm 0.4\%$  for nintedanib and placebo, respectively. Baseline comorbidities and SSc-related organ manifestations as well as discontinuation data at 52 weeks are available in Supplementary Results Tables S7–9.

Table 1  
Summary of baseline demographics of patients in the SENSICIS® trial

	<b>Patients included in joint models</b>  (N = 574) <sup>a</sup>	<b>Patients with all-cause hospitalisation events or death</b>  (n = 78)	<b>Patients with SSc-related hospitalisation events or death</b>  (n = 42)	<b>Patients with admission to ER or hospital followed by admission to ICU or death</b>  (n = 75)
Sex, n (%)				
Female	431 (75.1)	50 (64.1)	28 (66.7)	51 (68.0)
Age, years	53.9 ± 12.2	56.1 ± 12.0	56.1 ± 12.0	54.4 ± 11.6
Diffuse cutaneous SSc, n (%)	298 (51.9)	39 (50.0)	21 (50.0)	38 (50.7)
Time since the onset of the first non-Raynaud's symptom, years	3.5 ± 1.7	3.5 ± 1.9	3.2 ± 2.0	3.6 ± 1.7
Extent of fibrosis of the lungs on HRCT, %	36.0 ± 21.2	35.9 ± 20.2	38.5 ± 21.2	36.3 ± 21.9
FVC, mL	2501.2 ± 778.2	2532.0 ± 787.2	2498.2 ± 817.2	2455.7 ± 693.5
FVC, % predicted	72.5 ± 16.7	72.0 ± 16.4	70.5 ± 18.7	70.9 ± 16.7
DL <sub>CO</sub> , % predicted <sup>b</sup>	53.1 ± 15.1	48.4 ± 13.2	47.7 ± 12.6	49.2 ± 13.5
ATA positive, n (%) <sup>c</sup>	349 (60.8)	42 (53.8)	24 (57.1)	43 (57.3)
mRSS <sup>d</sup>	11.1 ± 9.0	12.3 ± 11.1	13.2 ± 11.6	11.6 ± 9.0
Total score on the SGRQ <sup>e</sup>	39.9 ± 20.4	44.3 ± 18.8	41.3 ± 19.9	47.9 ± 17.9
High-sensitivity C-reactive protein, mg/L <sup>f</sup>	6.2 ± 15.2	10.6 ± 30.4	14.5 ± 40.5	10.6 ± 31.4

Patients included in joint models (N = 574) <sup>a</sup>	Patients with all-cause hospitalisation events or death (n = 78)	Patients with SSc-related hospitalisation events or death (n = 42)	Patients with admission to ER or hospital followed by admission to ICU or death (n = 75)
Data are mean ± SD unless otherwise stated.			
<sup>a</sup> Data on some variables were not available for all patients.			
<sup>b</sup> The DL <sub>CO</sub> value was corrected for the haemoglobin level. DL <sub>CO</sub> values were available for 567 patients in total, 77, 41 and 74 patients with all-cause hospitalisation events or death, SSc-related hospitalisation events or death, and admission to ER or hospital followed by admission to ICU or death, respectively.			
<sup>c</sup> Historical information on ATA status was used, or, if this information was not available to the trial sites, it was provided by a central laboratory.			
<sup>d</sup> Scores were available for 572 patients in total, 77 and 74 patients with all-cause hospitalisation events or death, and admission to ER or hospital followed by admission to ICU or death, respectively.			
<sup>e</sup> Total scores on the SGRQ range from 0 to 100, with higher scores indicating worse health-related quality of life. Scores were available for 563 patients in total, 75 and 73 in patients with all-cause hospitalisation events or death, and admission to ER or hospital followed by admission to ICU or death, respectively.			
<sup>f</sup> High-sensitivity C-reactive protein values were available for 529 patients in total, 71, 39 and 66 patients with all-cause hospitalisation events or death, SSc-related hospitalisation events or death, and admission to ER or hospital followed by admission to ICU or death, respectively.			
ATA, anti-topoisomerase I antibody; DL <sub>CO</sub> ; diffusion capacity of the lungs for carbon monoxide; ER, emergency room; FVC, forced vital capacity; HRCT, high-resolution computed tomography; ICU, intensive care unit; mRSS, modified Rodnan Skin Score; SD, standard deviation; SGRQ, St. George's Respiratory Questionnaire; SSc, systemic sclerosis.			

## Joint model analysis

Six joint models using the estimated slope of FVC decline as the shared parameter were fitted. Low numbers of reported events precluded stable model fits for the endpoints time to first admission to hospital followed by admission to ICU or death (n = 11), and time to first admission to hospital followed by use of mechanical ventilation or death (n = 7).

At 52 weeks, 78 (13.7%) patients either had an all-cause hospitalisation event or died. Of these, 42 experienced a hospitalisation event or death related to SSc, accounting for 7.4% of patients included in the respective joint model. Seventy-five patients were admitted to ER or hospital (including all-cause

hospitalisation patients) followed by ICU or death, accounting for 13.1% of patients included in the respective joint model (Table 2).

Table 2

Association between slope of FVC% predicted and risk of first hospitalisation endpoints over 52 weeks

	<b>Time to first all-cause hospitalisation or death</b> (n = 568)	<b>Time to first SSc-related hospitalisation or death</b> (n = 570)	<b>Time to first admission to ER or admission to hospital followed by admission to ICU or death</b> (n = 572)
<b>Longitudinal sub-model<sup>a</sup></b>			
Estimated slope difference nintedanib vs. placebo (95% CI)	1.16 (0.00, 2.32)	1.44 (0.33, 2.55)	1.33 (0.18, 2.48)
P-value	0.0497	0.01	0.02
<b>Time to event sub-model<sup>b</sup></b>			
Number of patients with event, n (%)	78 (13.7)	42 (7.4)	75 (13.1)
Change in FVC% predicted vs. no change, HR (95% CI)			
1-unit decrease	1.13 (1.07, 1.18)	1.14 (1.07, 1.21)	1.05 (0.98, 1.12)
3-unit decrease	1.43 (1.24, 1.65)	1.48 (1.23, 1.77)	1.15 (0.95, 1.41)
5-unit decrease	1.81 (1.42, 2.30)	1.91 (1.41, 2.60)	1.27 (0.91, 1.76)
P-value	< 0.0001	< 0.0001	0.15
Data collected during treatment period.			
<sup>a</sup> Random effects normal linear model of FVC% predicted with predictor variables ATA status and FVC% predicted at baseline, a separate slope for patients on treatment, trajectories modelled by a linear trend, and an unstructured variance – covariance matrix.			
<sup>b</sup> Piecewise exponential baseline hazard, stratified by ATA status, and endogenous time-dependent covariate FVC% predicted as estimated slope of the longitudinal response.			
ATA, anti-topoisomerase antibody; CI, confidence interval; ER, emergency room; FVC, forced vital capacity; HR, hazard ratio, ICU, intensive care unit; SSc, systemic sclerosis.			

We observed a statistically significant relationship between FVC decline and time to first all-cause hospitalisation or death during 52 weeks of the SENSICIS® trial, with a 3-unit decline in FVC% predicted corresponding to a 1.43-fold increase in the risk of an event (hazard ratio [HR] 1.43; 95% confidence interval [CI] 1.24, 1.65;  $P < 0.0001$ ; Table 2). These values were consistent with those calculated over the whole trial (3-unit FVC% predicted decline: 1.47-fold increased risk; 95% CI 1.25, 1.74;  $P < 0.0001$ ; Table 3). FVC decline was also significantly associated with time to first SSc-related hospitalisation or death during 52 weeks of the SENSICIS® trial, with a 3-unit decline in FVC% predicted corresponding to a 1.48-fold increase in the risk of an event (HR 1.48; 95% CI 1.23, 1.77;  $P < 0.0001$ ). Corresponding data for 1- and 5-unit FVC% predicted declines are shown in Table 2. These findings were consistent with those calculated over the whole trial (3-unit FVC% predicted decline: 1.60-fold increased risk; 95% CI 1.29, 1.98;  $P < 0.0001$ ; Table 3). There was no association found between FVC decline and the time to first admission to ER or admission to hospital followed by admission to ICU or death at either 52 weeks or whole trial ( $P = 0.1549$  and  $P = 0.3376$ , respectively). HRs for varying values of FVC decline are visualised in Fig. 1. The estimated slope difference for nintedanib versus placebo in the longitudinal FVC% predicted sub-model was statistically significant at both time points, indicating that the rate of FVC decline was slower with nintedanib (Tables 2 and 3).

Table 3

Association between slope of FVC% predicted and risk of first hospitalisation endpoints over the whole trial

	Time to first hospitalisation or death (n = 568)	Time to first SSc-related hospitalisation or death (n = 570)	Time to first admission to ER or admission to hospital followed by admission to ICU or death (n = 572)
<b>Longitudinal sub-model<sup>a</sup></b>			
Estimated slope difference nintedanib vs. placebo (95% CI)	1.07 (0.10, 2.05)	1.19 (0.27, 2.12)	1.18 (0.23, 2.13)
P-value	0.03	0.01	0.02
<b>Time to event sub-model<sup>b</sup></b>			
Number of patients with event, n (%)	103 (18.1)	56 (9.8)	90 (15.7)
Change in FVC% predicted vs. no change, HR (95% CI)			
1-unit decrease	1.14 (1.08, 1.20)	1.17 (1.09, 1.26)	1.04 (0.96, 1.13)
3-unit decrease	1.47 (1.25, 1.74)	1.60 (1.29, 1.98)	1.12 (0.89, 1.43)
5-unit decrease	1.91 (1.44, 2.51)	2.18 (1.52, 3.13)	1.21 (0.82, 1.81)
P-value	< 0.0001	< 0.0001	0.34
Data collected during treatment period.			
<sup>a</sup> Random effects normal linear model of FVC% predicted with predictor variables ATA status and FVC% predicted at baseline, a separate slope for patients on treatment, trajectories modelled by a linear trend, and an unstructured variance - covariance matrix.			
<sup>b</sup> Piecewise exponential baseline hazard, stratified by ATA status, and endogenous time-dependent covariate FVC% predicted as estimated slope of the longitudinal response.			
ATA, anti-topoisomerase antibody; CI, confidence interval; ER, emergency room; FVC, forced vital capacity; HR, hazard ratio, ICU, intensive care unit; SSc, systemic sclerosis.			

In additional joint models using the estimated current value of FVC% predicted as the shared parameter (which ignore the individual dynamics), FVC was not statistically significantly associated with the risk of any hospitalisation events or death over 52 weeks (all-cause:  $P = 0.29$ ; SSc-related:  $P = 0.13$ ; admission to ER or hospital followed by ICU:  $P = 0.22$ ; Supplementary Results S10).

## Discussion

To the best of our knowledge, this is the first study to assess the impact of FVC changes on the risk of hospitalisation in SSc-ILD. Our joint model approach using data from the SENSICIS® trial showed that a decline in FVC% predicted corresponded to a statistically significant increase in the risk of all-cause and SSc-related hospitalisation or death during the treatment period. This is a new finding in SSc and is consistent with data in IPF [30]; it is also clinically important since hospitalisation rate is one of the most important outcomes for patients. We also observed a statistically significant treatment effect of nintedanib on FVC decline, mirroring the results from the SENSICIS® trial in which nintedanib reduced the rate of FVC decline compared with placebo [20]. Our findings suggest that even small reductions in the decline of FVC% predicted (1–3 units) in response to a treatment intervention can result in relevant reductions in the risk of hospitalisation.

There was no association between the rate of FVC decline and the risk of admission to ER or hospital followed by admission to ICU or death. Although ILD is part of a series of systemic complications in SSc that can lead to hospitalisations, the proportion of ILD-related hospital or ER admissions was not recorded in SENSICIS®, limiting further analysis of this finding. In addition, patients may have required hospitalisation for procedures and special medication administration, but this was also not recorded.

The baseline characteristics of all patients with hospitalisation events were similar to the overall population. Baseline FVC% predicted and  $DL_{CO}$  values were numerically slightly lower in patients with hospitalisation events compared with the overall population. Over 20% of hospitalised patients had infections and infestations at baseline, which may be related to concomitant immunosuppression or more severe disease. Furthermore, the trial discontinuation rate was higher in patients who had an all-cause or SSc-related hospitalisation or death than in the overall population. Patients with all-cause or SSc-related hospitalisation events had numerically higher C-reactive protein levels and a higher proportion had elevated creatine kinase levels compared with the overall population. It is possible that patients who had an SSc-related hospitalisation or death may have had more complications related to more active inflammatory disease.

Our analysis used two different parameterisations of the association structure in the joint model. Importantly, we observed strong evidence in the primary analysis that the slope of the FVC decline is predictive of hospitalisation, whereas a secondary analysis exhibited no (or very little) evidence of the current FVC value as a predictor of hospitalisation. As an implication for clinical practice, this suggests that the dynamics of the decline in FVC play a larger role than singular FVC values in the assessment of

hospitalisation risk. It also underlines the importance of monitoring changes in FVC over time in clinical practice to assess the hospitalisation risk of individual patients.

Given the potential relationship between the change in FVC and the risk of hospitalisation, we evaluated the validity of FVC as a surrogate endpoint for the clinically important hospitalisation-associated endpoints according to the three levels of surrogacy defined by Taylor and Elston [24]. Since we have observed a statistically significant association between the surrogate outcome of FVC decline and time to hospitalisation events (which is a patient-related outcome) our findings meet the second, intermediate level of the endpoint surrogacy criteria. With an established link between these outcomes, further investigations are required to evaluate whether the slowing effect of nintedanib on FVC decline directly corresponds to a reduction in the risk of a hospitalisation event.

Our study has the following limitations. First, the analysis was limited to the data collected in the SENSICIS® trial, where data on the reasons for hospital admissions were not specific and were limited to whether they were SSc-related or not. In addition, data collection was restricted to the duration of the clinical trial. Second, the SSc-ILD population had relatively preserved lung function and many were receiving immunosuppressant therapy, which may have slowed down ILD progression but also may have increased the risk for infection related hospitalisations. Finally, since these results were obtained from a controlled clinical trial environment, replication in clinical practice would be desirable as the association between FVC decline reduction and risk of hospitalisation reduction is of great clinical importance.

## Conclusions

In conclusion, our joint modelling approach indicated that a decline in FVC has a clinically relevant association with the risk of all-cause and SSc-related hospitalisation or death in patients with SSc-ILD in the context of the SENSICIS® trial. It also provides evidence that FVC decline may be used as a surrogate endpoint for time to first hospitalisation, a clinically relevant parameter, though further validation is required. Our analysis further suggests that slowing FVC decline may prevent hospitalisations in patients with SSc-ILD and supports the value of serial FVC measurement in randomised controlled trials.

## Abbreviations

ATA, anti-topoisomerase I antibody; CI, confidence interval; CTD, connective tissue disease;  $DL_{CO}$ , diffusing capacity of the lung for carbon monoxide; ER, emergency room; FVC, forced vital capacity; HR, hazard ratio; HRQoL, health-related quality of life; ICU, intensive care unit; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PRO, patient-reported outcome; SD, standard deviation; SSc, systemic sclerosis.

## Declarations

### Ethics approval and consent to participate

The SENSICIS<sup>®</sup> trial was conducted in accordance with the trial protocol, the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation, and was approved by local authorities. Written informed consent was obtained from all patients before study entry.

### **Consent for publication**

Not applicable.

### **Availability of data and materials**

To ensure independent interpretation of clinical study results, Boehringer Ingelheim International GmbH (BI) grants all external authors access to all relevant material, including participant-level clinical study data, and relevant material as needed by them to fulfil their role and obligations as authors under the International Committee of Medical Journal Editors (ICMJE) criteria. Furthermore, clinical study documents (e.g. study report, study protocol, statistical analysis plan) and participant clinical study data are available to be shared after publication of the primary manuscript in a peer-reviewed journal and if regulatory activities are complete and other criteria met per the BI Policy on Transparency and Publication of Clinical Study Data: <https://trials.boehringer-ingelheim.com/>. Prior to providing access, documents will be examined, and, if necessary, redacted and the data will be de-identified, to protect the personal data of study participants and personnel, and to respect the boundaries of the informed consent of the study participants. Clinical Study Reports and Related Clinical Documents can also be requested via the link <https://trials.boehringer-ingelheim.com/>. All requests will be governed by a Document Sharing Agreement. Bona fide, qualified scientific and medical researchers may request access to de-identified, analysable participant clinical study data with corresponding documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data are shared in a secured data-access system for a limited period of 1 year, which may be extended upon request. Researchers should use the <https://trials.boehringer-ingelheim.com/> link to request access to study data.

### **Competing interests**

MK reports consultancy fees from Boehringer Ingelheim (BI), Roche and Galapagos, outside the submitted work. FDG reports research grants from Capella Biosciences, Mitsubishi-Tanabe, Chemomab and Kymab; and consultancy fees from Actelion, BI, AstraZeneca, Mitsubishi-Tanabe, Capella, Chemomab, outside the current work. DK reports research grants from Immune Tolerance Network, Bayer, Horizon and Pfizer; consultancy fees from Acceleron, Actelion, Abbvie, Amgen, Bayer, BI, CSL Behring, Corbus, Gilead, Galapagos, Genentech/Roche, GlaxoSmithKline, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis and United Therapeutics; and employment at Eicos Science/CiviBioPharma, outside the submitted work. WW has nothing to disclose. LKH reports research grants BI, Corbus, Cumberland, CSL Behring, Kadmon and Medpace; and advisory board fees from BI, outside the submitted work. YA reports consultancy fees from BI, during the conduct of the study. MA and NS are employees of

BI International GmbH. CS is employee of Boehringer Ingelheim Pharma GmbH & Co. KG. CM is an employee of mainanalytics GmbH, which is a service provider contracted by BI.

## Funding

This analysis was supported by Boehringer Ingelheim International GmbH. MK, FDG, CM, DK, WW, LKH and YA did not receive payment for the development of the manuscript.

## Authors' contributions

Study design: MA, NS, CS. Data analysis: CM, CS. Data interpretation: all authors. Writing of the manuscript: all authors. Read and approved manuscript before submission: all authors.

## Acknowledgements

Writing, editorial support and formatting assistance was provided by Hannah Cook, PhD, of Meditech Media, which was contracted and funded by Boehringer Ingelheim International GmbH (BI). BI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Statistical input by Elvira Erhardt of mainanalytics and statistical programming support by Show Reddy Maramreddy of BI are gratefully acknowledged.

## References

1. Hughes M, Herrick AL. Systemic sclerosis. *Br J Hosp Med*. 2019;80(9):530-36.
2. Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. *Nat Rev Rheumatol*. 2018;14(9):511-27.
3. Gayle A, Schoof N, Alves M, Clarke D, Raabe C, Das P, et al. Healthcare resource utilization among patients in England with systemic sclerosis-associated interstitial lung disease: A retrospective database analysis. *Adv Ther*. 2020;37(5):2460-76.
4. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. *Ann Rheum Dis*. 2017;76(11):1897-905.
5. Ahmed SS, Johnson SR, Meaney C, Chau C, Marras TK. Lung function and survival in systemic sclerosis interstitial lung disease. *J Rheumatol*. 2014;41(11):2326-28.
6. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. *Arthritis Rheumatol*. 2017;69(8):1670-78.
7. Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. *Eur Respir J*. 2020;55(5):1902026.
8. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. *J Rheumatol*. 2007;34(5):1194-200.

9. Kafaja S, Clements PJ, Wilhalme H, Tseng C-H, Furst DE, Kim GH, et al. Reliability and minimal clinically important differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). *Am J Respir Crit Care Med*. 2018;197(5):644-52.
10. Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. *J Rheumatol*. 2015;42(11):2168-71.
11. Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. *Eur Respir J*. 2016;47(2):597-606.
12. Mittoo S, Frankel S, LeSage D, Strand V, Shah AA, Christopher-Stine L, et al. Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). *Curr Respir Med Rev*. 2015;11(2):175-83.
13. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014;69(5):428-36.
14. Saketkoo LA, Scholand MB, Lammi MR, Russell A-M. Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. *J Scleroderma Relat Disorders*. 2020;5(2 Suppl):48-60.
15. Kreuter M, Hoffmann-Vold A-M, Matucci-Cerinic M, Saketkoo L, Highland K, Wilson H, et al. Health-related quality of life in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): Impact of lung function on patient-reported outcomes in a randomized phase III trial. *Arthritis Rheumatol*. 2019;71:1656.
16. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. *Respir Res*. 2019;20(1):59.
17. Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement. *J Rheumatol*. 2018;45(2):235-41.
18. Zhou Z, Fan Y, Thomason D, Tang W, Liu X, Zhou Z-Y, et al. Economic burden of illness among commercially insured patients with systemic sclerosis with interstitial lung disease in the USA: a claims data analysis. *Adv Ther*. 2019;36(5):1100-13.
19. Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. *J Rheumatol*. 2012;39(12):2303-09.
20. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. *N Engl J Med*. 2019;380(26):2518-28.
21. Molenberghs G, Alonso A, Van der Elst W, Burzykowski T, Buyse M. Statistical evaluation of surrogate endpoints in clinical studies. In: Young W, Chen DG, editors. *Clinical Trial Biostatistics and Biopharmaceutical Applications*. New York: Chapman and Hall/CRC; 2014.

22. Papageorgiou G, Mauff K, Tomer A, Rizopoulos D. An overview of joint modeling of time-to-event and longitudinal outcomes. *Annu Rev Stat Appl.* 2019;6(1):223-40.
23. Chen Y, Postmus D, Cowie MR, Woehrl H, Wegscheider K, Simonds AK, et al. Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. *Eur Respir J.* 2020.
24. Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. *Health Technol Assess.* 2009;13(8):iii, ix-xi, 1-50.
25. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatol.* 2013;65(11):2737-47.
26. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YMRM, Draeger H, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. *Arthritis Res Ther.* 2010;12(5):R166.
27. Garcia-Hernandez A, Rizopoulos D. %JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses. *J Stat Softw.* 2018;84(12):29.
28. Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. *J Stat Softw.* 2010;35(9):33.
29. Sudell M, Kolamunnage-Dona R, Tudur-Smith C. Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis. *BMC Med Res Methodol.* 2016;16(1):168.
30. Lassenius MI, Toppila I, Pontynen N, Kasslin L, Kaunisto J, Kilpelainen M, et al. Forced vital capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. *Eur Clin Respir J.* 2020;7(1):1702618.

## Figures




Figure 1

Change in risk of first hospitalisation endpoints by decline in FVC% predicted a) all-cause hospitalisation or death; b) SSc-related hospitalisation or death; c) ER or hospital admission followed by ICU or death  
Data collected during treatment period over 52 weeks. CI, confidence interval; ER, emergency room; FVC, forced vital capacity; HR, hazard ratio; ICU, intensive care unit; SSc, systemic sclerosis.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [KreuterSENSCISJointmodelsupplementFINAL.docx](#)